Oroboros: An EIC Accelerator Grant for Measuring Mitochondria

Every cell in the body burns oxygen in its mitochondria, and when that machinery falters it shows up in diseases from diabetes to Parkinson's. Measuring how well mitochondria work is a niche, but a scientifically important one, and an Innsbruck company has supplied the instruments for it for three decades. Oroboros Instruments, founded by Erich Gnaiger in 1992, sells the O2k, a two-chamber respirometer that tracks oxygen consumption of cells, tissue samples and isolated mitochondria with very high resolution.

In the 9 January 2019 cut-off of the EIC SME Instrument Phase 2, the Horizon 2020 programme that became the EIC Accelerator pilot later that year, Oroboros won a grant to turn the O2k into an all-in-one platform. The European Commission's list of SME Instrument Phase 2 winners names Oroboros as the only beneficiary of the project, NextGen-O2k. CORDIS records an EU contribution of €1,650,412.75 towards a total cost of €2,357,732.50, grant only, from 1 June 2019 to 31 October 2021. The stated aim was to "complete the development of NextGen-O2k and prepare its market launch in 2021".

Where Oroboros Stands Now

Oroboros is an active, owner-managed company. The Austrian business register lists it as registered, with Erich Gnaiger as managing director since 2000 and annual accounts filed every year, most recently for 2024 on 8 October 2025, according to the state's official publication platform and North Data. North Data also records that in September 2018 the business of Gnaiger's former sole proprietorship was transferred into the GmbH, and that Oroboros Holding GmbH became the sole shareholder. The accounts themselves could not be read free of charge, since North Data shows their figures only to paying customers, so revenue, profit and headcount could not be verified for this article.

The company's current activity is easy to document. Its online shop sells the NextGen-O2k Redox, the configuration that came out of the EU project, and from 1 to 3 July 2026 Oroboros trained distributor staff from Beijing in Innsbruck on the Q-, TPP-, PhotoBiology- and pH-Modules, according to the programme on the company's Bioblast wiki. Its website claims more than 1,700 instruments in more than 50 countries and more than 5,100 publications based on them.

The Technology: Oxygen First, Then Everything Else

The core of every Oroboros instrument is a polarographic oxygen sensor in a sealed glass chamber of 2 or 0.5 millilitres, kept at a set temperature to within ±0.002 °C. The company specifies a resolution of oxygen flux of ±1 picomole per second per millilitre and an oxygen concentration limit of 5 nanomolar. Researchers add substrates, uncouplers and inhibitors one after another, in what Oroboros calls SUIT protocols, and read off how each step of the respiratory chain performs. A fluorescence version, the O2k-FluoRespirometer, added membrane potential, hydrogen peroxide, calcium and ATP measurements in 2012, according to the project's technical page.

The NextGen-O2k adds three things. A Q-Module uses a three-electrode sensor to follow the redox state of coenzyme Q, the electron carrier at the centre of the respiratory chain, in real time while oxygen is measured; CORDIS calls it a "completely novel" sensor not on the market before. A NADH-Module measures the autofluorescence of NAD(P)H with ultraviolet light and a photodiode. A PhotoBiology-Module with its own red, blue and white light sources measures oxygen production by algae and chloroplasts. The company's product overview states that the Q- and NADH-Modules run only on the NextGen-O2k, not on the older O2k.

The main alternative in many laboratories is the Seahorse XF analyser of the US group Agilent, which measures oxygen in multi-well plates of attached cells. A 2022 study in PLoS One by researchers at Charles University in Prague with Erich Gnaiger, co-funded by the NextGen-O2k grant, compared the two on human fibroblasts. It found comparable respiration overall but a higher measured electron transfer capacity in the O2k, which the authors linked to the Seahorse's limit of two uncoupler titrations. The Seahorse's strength is throughput; the O2k's is resolution and flexible protocols, as the company's own platform comparison argues.

What the EIC Project Promised, and What CORDIS Shows

The Phase 2 grant followed a €50,000 SME Instrument Phase 1 study from February to May 2018. Its CORDIS summary set the commercial ambition: a 40% increase in staff and "overall revenues of €42 million in 3 years after market launch". At the time, the company said its instruments were sold in 49 countries and used by more than 570 laboratories, and that it had four prototypes of the new instrument.

The Phase 2 project was planned for 24 months and extended by five, according to the project's Bioblast page, which also dates the proposal to 9 January 2019, the pitch in Brussels to 15 February and the grant decision to 5 March. The final periodic report says the Q-, NADH- and PhotoBiology-Modules were developed and integrated with a rebuilt DatLab 8 software, tested with outside researchers, and documented in manuals and videos; "NextGen-O2k", "DatLab", "High-Resolution Respirometry" and "O2k" were registered as EU trade marks. It also says the company "explored the NextGen-O2k's potential as a medical device", and that no ISO certification was planned. The instrument was presented at a virtual NextGen-O2k Summit on 20 October 2021, eleven days before the project ended.

1. Q-Module for coenzyme Q redox stateDeliveredPart of the NextGen-O2k Redox package; taught at the 2026 distributor training.
2. NADH-ModuleDeliveredOn sale in the same package, with its own manual on Bioblast.
3. PhotoBiology-Module for algaeDeliveredSold as an add-on; a top-three nominee for the 2021 Tyrolean Innovation Award, per the company.
4. Market launch in 2021LateCORDIS in March 2022 gave a planned launch of March 2022; first all-in-one demo workshop in July 2022.
5. €42M revenue within three years of launchUnverifiedRevenue is not published.
6. Use as a medical deviceNot pursued publiclyExplored only; no certification announced.

On the technical brief, the project delivered: all three modules exist, are sold and are still being taught to distributors five years later. The schedule slipped. CORDIS had promised a 2021 launch; its Results in Brief, published on 18 March 2022, said the launch was "planned for March 2022", and the first NextGen-O2k all-in-one demo workshop took place in Innsbruck on 1 and 2 July 2022. An exact date of first sale could not be found.

What Oroboros Has Achieved Since the Award

The clearest signal is scientific rather than financial. The grant co-funded peer-reviewed work such as the Prague fibroblast study, and Oroboros scientists presented simultaneous measurements of oxygen flux and Q- and NADH-redox states with the NextGen-O2k at the MiP2023 conference, according to the abstract. Within the project the company also started an open-access journal, Bioenergetics Communications, whose editors include Gnaiger and which was still publishing in 2026. CORDIS lists it as a project result; it also places a company-run journal in the same field as the company's products.

Oroboros won regional recognition for the work: the Standortagentur Tirol's Cluster Award in Life Sciences for the NextGen-O2k project in 2019, and again in 2022 for Oxia, an oxygen regime controller developed with its long-time mechatronics partner WGT-Elektronik, according to the company. Its user base, by its own counts, grew from more than 570 laboratories in 2018 to more than 720 today.

The Money

Oroboros financed the NextGen-O2k without outside investors. No venture round, EIC Fund investment or other equity has been reported, and the shareholder register shows only the founder's holding company. The 2019 grant was grant only; the company paid €707,319.75 of the project itself. Regional news site MeinBezirk reported in 2019 that Oroboros was the first Tyrolean company to lead an SME Instrument Phase 2 project and was selected from 1,848 applications in its round.

EU money has long been part of the company's research model. Besides the two SME Instrument grants, North Data lists Horizon 2020 participations on the role of mitochondria in tumour formation, on cancer research training and on non-alcoholic fatty liver disease, and Oroboros was a partner organisation in the PERICO Marie Skłodowska-Curie training network on peroxisomes, hosting early-stage researchers.

Why Europe Should Care

Oroboros builds research instruments in Austria with Austrian partners for hardware and software, in a field where the best-known alternative comes from a US group. That fits the Commission's July 2025 strategy "Choose Europe for Life Sciences", which aims to make the EU the most attractive place for life sciences by 2030 and to strengthen research infrastructure. The PhotoBiology-Module ties into a second policy line: in November 2022 the Commission adopted its communication "Towards a strong and sustainable EU algae sector", with 23 actions including closing research and technology gaps. Whether algae producers, rather than university laboratories, buy the module has not been documented.

The Verdict

Oroboros Instruments has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.